ライフサイエンスコーパス: femoral vein

1 was randomized (136 subclavian vein and 134 femoral vein).

2 ization of the right femoral artery and left femoral vein.

3 denosine 140 mcg/kg per minute via a central femoral vein.

4 ges acquired within the pump circuit and the femoral vein.

5 of the right superficial femoral artery and femoral vein.

6 ) in PBS or a PBS-alone injection into right femoral vein.

7 We infused hyperosmolar sucrose via the femoral vein.

8 oxide in a manner similar to that of porcine femoral vein.

9 heter with a snare introduced via the common femoral vein.

10 ers inserted in the brachial artery and both femoral veins.

11 atic or asymptomatic DVT in the popliteal or femoral veins.

12 elial cells or endothelial cells of isolated femoral veins.

13 Two 8-Fr catheters were placed into the femoral veins.

14 vigation-guided mapping/ablation with normal femoral vein access (49); and Group C, remote magnetic n

15 Using femoral vein access, a steerable guide catheter was plac

16 eight healthy volunteers once with bilateral femoral vein and artery catheters during a 3-h basal per

17 Catheters were placed in the femoral vein and artery, and in the pulmonary artery.

18 e then tracheostomized and cannulated in one femoral vein and artery.

19 Bolus (0.3 mL) was injected into the femoral vein and hemodynamics monitored.

20 uptake and definitive in vivo images of both femoral vein and pulmonary thrombi show that 99mTc-P748

21 catheters were surgically implanted into the femoral vein and sepsis was induced by cecal ligation an

22 catheters were inserted into the jugular and femoral veins and femoral artery.

23 e, sampling (artery and portal, hepatic, and femoral veins) and infusion (vena cava, duodenum) cathet

24 rosal sinus, and the internal jugular vein), femoral vein, and radial artery of patients undergoing i

25 d, and cannulated in one femoral artery, one femoral vein, and the right jugular vein.

26 Saline injection via the right femoral vein appears to have a higher diagnostic yield f

27 othelial cells and when placed into isolated femoral vein as well as increased endothelial cell monol

28 embolic stroke and received treatment via a femoral vein at 4 h post-stroke.

29 es were taken from the LA, right atrium, and femoral vein at baseline and at 15 min in all 3 groups.

30 In contrast,femoral vein ATP infusion did not alter LBF, (.)Q or MAP

31 re obtained from one femoral artery and both femoral veins before and during the clamp.

32 Systemic (femoral vein) but not coronary sinus tumor necrosis fact

33 They underwent tracheostomy, jugular and femoral vein cannulation, femoral artery cannulation, ca

34 ture suggest that thrombosis associated with femoral vein catheterization should be considered when c

35 of a heretofore undescribed complication of femoral vein catheterization, phlegmasia cerulea dolens

36 er risk of pneumothorax than jugular-vein or femoral-vein catheterization.

37 mon femoral vein (CFV), proximal superficial femoral vein (CFV), mid-SFV, distal SFV, and popliteal v

38 s were categorized at five locations: common femoral vein (CFV), proximal superficial femoral vein (C

39 n alone as a placebo by injection into right femoral vein, directly into the left ventricular (LV) ca

40 Glutathione also elevated cGMP levels in the femoral vein during ACH infusion from 17.6 +/- 3 to 23.3

41 ) was infused over the next 3 min of CPR via femoral vein followed by up to three defibrillation atte

42 958 in the internal jugular and 3,188 in the femoral vein for a total of 113,652 catheter days.

43 The animals had a catheter inserted into the femoral vein for administration of 5-HT (0.00375 mg) and

44 serted either in the internal jugular or the femoral vein had greater risk to be colonized than cathe

45 dvance the delivery sheath beyond the common femoral vein in 1).

46 TPV implant was via the femoral vein in 17 patients, the right internal jugular

47 ed into the subclavian, internal jugular, or femoral vein in two randomized trials during 1998-2000 w

48 re unit (ICU) to the subclavian, jugular, or femoral vein (in a 1:1:1 ratio if all three insertion si

49 1 and femoral artery in 20) and anterograde (femoral vein) in 2.

50 erval [0.30-0.70], I=0%; subclavian vein vs. femoral vein, incidence density ratio 0.27; 95% confiden

51 type second harmonic ultrasound system after femoral vein injection of AF0145 (10 to 40 mg) in 13 clo

52 Additionally, following femoral vein injury, Tfpi(+/-);F8(-/-) mice with Tfpi(-/

53 t puncture set was introduced from the right femoral vein into the left renal vein.

54 Animals are first anesthetized, then one femoral vein is exposed and subjected to a standardized,

55 The femoral vein is widely accepted as an insertion site wit

56 ypass-related complications (cerebral edema, femoral vein laceration).

57 After thrombolysis, 99 iliac and five femoral vein lesions were treated with stents.

58 subclavian, 3053 internal jugular, and 1554 femoral vein) met the inclusion criteria, one of which w

59 6), common femoral (n = 27), and superficial femoral veins (n = 4).

60 , n=37; and Group 3, cadaveric cryopreserved femoral vein, n=11.

61 red, and changes in leg blood flow (LBF) and femoral vein nitric oxide nitrite plus nitrate (NOx) flu

62 genic injury was subsequently induced in the femoral vein of each mouse and the area (size) of thromb

63 of the kinetics of a thrombus induced in the femoral vein of the animal.

64 inserted into both femoral arteries and one femoral vein of the support rat.

65 inetics of thrombus formation induced in the femoral veins of the experimental mice were compared.

66 ion at rest, (3) passive exercise (n=10), (4)femoral vein or artery ATP infusion (n=6), and (5) cycli

67 ide) was administered into the right atrium, femoral vein, or endotracheal tube.

68 In 10 patients, femoral vein plasma cyclic guanylate monophosphate (cGMP

69 Placebo administered into the femoral vein resulted in a significant increase in perce

70 rine administration via the right atrium and femoral vein resulted in significant increases in plasma

71 ous conduits must be utilized, cryopreserved femoral veins seem to provide superior patency rates.

72 The needle was introduced via a 12-F femoral vein sheath and advanced into the IVC by using a

73 l, vaginal mucosa, and clitoris assessments; femoral vein signal intensity measurements; relative reg

74 amples were obtained simultaneously from the femoral vein (systemic sample) and the coronary sinus (l

75 of peak oxygen uptake while leg blood flow (femoral vein thermodilution), mean arterial blood pressu

76 Dogs with unilateral femoral vein thrombi were allocated into three groups: (

77 and purity and provided definitive images of femoral vein thrombi within 20 min and pulmonary thrombi

78 ical and yield purity and provided images of femoral vein thrombin in the canine model by 1 hr postin

79 Femoral vein thrombus-to-blood and thrombus-to-muscle ra

80 eous entry into the abdominal aorta from the femoral vein through the adjoining inferior vena cava.

81 s employed in a percutaneous approach from a femoral vein to pierce the right atrial appendage.

82 underwent ferric chloride application on the femoral vein to trigger thrombosis.

83 In the femoral vein, W was gradually amplified in the lipopolys

84 One femoral vein was cannulated with a pulmonary artery flot

85 lood samples from the coronary sinus and the femoral vein were collected at those time points and the

86 atheters inserted in the internal jugular or femoral veins when catheters are not used for drawing bl

87 Biopsies were performed via the ipsilateral femoral vein with a renal biopsy set designed for transj

88 the brachial artery and internal jugular and femoral veins with plasma and RBC nitric oxide metabolit

89 m cannulae in the inferior vena cava and the femoral veins, with a tie on the inferior vena cava sepa